Phase II Study of ABI-007 Plus Sunitinib as First Line Treatment for Non-Small Cell Lung Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2018
At a glance
- Drugs Paclitaxel (Primary) ; Sunitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Mar 2011 Planned End Date changed from 1 Dec 2008 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 04 Jan 2011 Planned end date changed from 1 Sep 2015 to 1 Dec 2008 as reported by ClinicalTrials.gov.
- 01 Mar 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.